Dexamethasone treatment regimen and clinical outcomes in children with asthma exacerbations

Clinical question

For children discharged from the emergency department after treatment of an asthma exacerbation with dexamethasone, is prescribing a second dose associated with fewer short-term return visits or hospitalizations than a one-dose strategy?

Bottom line

In a retrospective cohort of 2,063 children discharged from two pediatric emergency departments after dexamethasone treatment, a second prescribed dose was not associated with fewer 1-to-14-day ED revisits or hospitalizations after propensity weighting. The findings support considering a one-dose strategy for many discharged children, but they do not establish causal noninferiority or show that one dose is sufficient for every child.

PICO

Population. Children aged 2 to 20 years discharged after an ED asthma visit at two pediatric emergency departments.

Intervention. A discharge strategy that included a second dexamethasone dose.

Comparator. A one-dose dexamethasone strategy.

Outcomes. ED revisits and hospitalizations from day 1 through day 14 after discharge, analyzed after propensity weighting.

What did the study find?

The study included 2,063 discharged children; 1,277 received the two-dose strategy. After weighting, ED revisits were 5.2% with one dose and 5.7% with two doses. Hospitalizations were 0.85% and 0.83%, respectively. Neither result demonstrated an outcome improvement from routinely prescribing the second dose.

The observed revisit and hospitalization proportions are close, and the confidence intervals include modest benefit and modest harm. This is a practical comparison for discharge planning, but it should not be converted into a claim that the two strategies are proven equivalent.

Appraisal

This was a retrospective, two-site cohort. The choice to prescribe a second dose was not randomized, so clinicians may have selected it for children who appeared to have different severity, reliability, access, prior response, or follow-up needs. Propensity weighting addresses measured differences, but it cannot account for unmeasured factors or fully recreate random allocation.

The short return-visit window is relevant to discharge outcomes, although it does not capture every symptom, medication-adherence issue, or later exacerbation. The findings apply to children discharged from the two participating pediatric EDs after dexamethasone; they should not be extended automatically to admitted patients, other steroid regimens, or every local pathway.

The reported hospitalization percentages are 0.85% and 0.83%. Some secondary reporting is internally inconsistent; interpret exploratory details cautiously.

Practical interpretation

For many children who are clinically ready for discharge after dexamethasone-treated asthma, a routine second outpatient dose did not show fewer returns or hospitalizations in this study. A one-dose approach can therefore be considered when it fits local practice, patient condition, caregiver instructions, access to follow-up, and clinician judgment.

This evidence does not replace individualized discharge assessment. Ensure families understand the rescue plan, expected course, return precautions, and follow-up. The study does not provide a reason to make an unqualified statement that a second dose is never appropriate, and it does not prescribe a universal regimen for all ages or severities.

Limits to carry forward

• Retrospective design means residual confounding remains possible despite propensity weighting.
• The results are associations, not a randomized noninferiority finding.
• Two pediatric EDs and discharged patients define the population; external applicability is limited.
• Some secondary reporting is internally inconsistent; interpret exploratory details cautiously.

Learning pearls

1. “No observed improvement” is not the same as “proven equivalent.”
2. Use the observed outcomes: revisit 5.2% versus 5.7%; hospitalization 0.85% versus 0.83%.
3. Match steroid-discharge decisions to the individual child and local pathway.
4. Do not substitute this study for asthma action plans, return precautions, or follow-up planning.

ACPE UAN: 0683-0000-26-036-H01-P

---

Study source: PMID:41575401